Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination

Main Article Content

Angela Yen Moore
Stephen Moore


actinic keratosis, photodynamic therapy, aminolevulinic acid hydrochloride


Abstract not available.


1. Dodds, A., A. Chia, and S. Shumack, “Actinic keratosis: rationale and management.” Dermatol Ther (Heidelb). 2014. 4(1):11-31.

2. Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. “A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BFRhodoLED(®) lamp.” Br J Dermatol. 2016:175(4):696-705.

3. Reinhold U. “A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis.” Future Oncol. 2017:13(27):2413-2428

4. Nestor et al. “Safety and efficacy of aminolevulinic acid 10% topical gel versus aminolevulinic acid 20% topical solution followed by blue-light photodynamic therapy for the treatment of actinic keratosis on the
face and scalp: a randomized, double-blind study.” J Clin Aesthet Dermatol. 2019;12:32-38.

5. Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact
application of 5-aminolevulinate. J Biomed Opt. 2010;15(5):051607.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.